XML 96 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration and License Agreements - Additional Information (Details)
$ in Thousands
12 Months Ended
Mar. 31, 2020
USD ($)
Target
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Collaboration And License Agreements [Line Items]      
Collaboration and license revenue   $ 10,141 $ 1,085
Incurred costs   58,782 27,318
Deferred revenue, current portion   $ 11,410 10,627
Novartis      
Collaboration And License Agreements [Line Items]      
License agreement date Mar. 31, 2020    
Upfront payment received $ 20,000    
Negotiation period   180 days  
Expects research term 3 years    
Collaboration and license revenue   $ 9,800 800
Incurred costs   3,300 200
Deferred revenue, current portion   11,400 10,600
Long-term deferred revenue   $ 1,500 $ 8,800
Novartis | Maximum      
Collaboration And License Agreements [Line Items]      
Number of targets identified | Target 3    
Novartis | Research Funding      
Collaboration And License Agreements [Line Items]      
Upfront payment received $ 10,000